Huagongshe화공사 화학 정보 인쇄 보고서 · 연구 참고용
(Tetrahydrofuran-3-yl)methanamine → 1-(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)-N-((tetrahydrofuran-3-yl)methyl)methanamine
참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|---|---|---|
| 반응물 | (Tetrahydrofuran-3-yl)methanamine | HCID 10898660 | — |
| 반응물 | 4-(8-(bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine | HCID 59605812 | — |
| 생성물 | 1-(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)-N-((tetrahydrofuran-3-yl)methyl)methanamine | HCID 59606034 | — |
반응 단계
4-(8-(Bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine (50 mg) was reacted with (tetrahydrofuran-3-yl)methanamine via General Procedure E to give 6.9 mg of 297 following reverse phase purification. MS (Q1) 463.2 (M)+
출처 및 근거
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|---|
| 특허 번호 | US08173650B2 |
| 출처 데이터셋 | uspto-grants-2012_05 |
| ORD ID | ord-683a20259388480fa4870f9e908a5517 |
| 출처 메모 | uspto-grants-2012_05 |